1. Apoptosis
    PI3K/Akt/mTOR
    MAPK/ERK Pathway
    Stem Cell/Wnt
  2. TNF-alpha
    Akt
    ERK

TIC10 (Synonyms: ONC-201)

Cat. No.: HY-15615A Purity: 99.68%
Data Sheet SDS Handling Instructions

TIC10 is a potent, orally active, and stable TRAIL inducer, also inhibits Akt and ERK activity.

For research use only. We do not sell to patients.
TIC10 Chemical Structure

TIC10 Chemical Structure

CAS No. : 1616632-77-9

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $77 In-stock
5 mg $70 In-stock
10 mg $100 In-stock
50 mg $300 In-stock
100 mg $450 In-stock
200 mg $720 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Other Forms of TIC10:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

TIC10 is a potent, orally active, and stable TRAIL inducer, also inhibits Akt and ERK activity.

IC50 & Target

TRAIL, Akt, Erk[1]

In Vitro

TRAIL-inducing compound 10 (TIC10), a potent, orally active, and stable small molecule that transcriptionally induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in a p53-independent manner and crosses the blood-brain barrier. TIC10 induces a sustained up-regulation of TRAIL in tumors and normal cells that may contribute to the demonstrable antitumor activity of TIC10. TIC10 inactivates kinases Akt and extracellular signal-regulated kinase (ERK), leading to the translocation of Foxo3a into the nucleus, where it binds to the TRAIL promoter to up-regulate gene transcription. TIC10 is an efficacious antitumor therapeutic agent that acts on tumor cells and their micro-environment to enhance the concentrations of the endogenous tumor suppressor TRAIL. TIC10 as a TRAIL-inducing compound. TIC10 causes a dose-dependent increase in TRAIL mRNA and induces TRAIL protein localization on the cell surface of several cancer cell lines in a p53-independent manner. Besides, both pAkt and pERK are down-regulated by TIC10 treatment in a dose-dependent manner. TIC10 also causes a down-regulation of the total expression of ERK[1].

In Vivo

In DLD-1 colon cancer xenografts, TIC10 induces tumor stasis at 1 week after treatment, whereas TRAIL-treated tumors progress after a single dose. A single dose of TIC10 also induces a sustained regression of the SW480 xenograft and is equally effective when delivered by intraperitoneal or oral route, suggesting favorable oral bioavailability for TIC10. Titration of a single oral dose of TIC10 in the HCT116 xenograft model reveals sustained antitumor efficacy at 25 mg/kg. Exposure to oral TIC10 at 25 mg/kg weekly for 4 weeks in immunocompetent mice does not cause any changes in selected serum chemistry markers. The same oral dosing schedule is applied to Eμ-myc transgenic mice, which spontaneously develop meta-static lymphoma from weeks 9 to 12 of age, and TIC10 significantly (P=0.00789) prolongs the survival of these mice by 4 weeks[1].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02609230 Fox Chase Cancer Center Advanced Solid Tumors|Multiple Myeloma November 5, 2015 Phase 1
NCT02250781 Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey Solid Tumors January 2015 Phase 1
NCT02038699 Oncoceutics, Inc. Advanced Glioblastoma|Advanced Colorectal Cancer|Advanced Triple-negative Breast Cancer|Advanced Non-small Cell Lung Cancer Phase 1|Phase 2
NCT02863991 Oncoceutics, Inc. Multiple Myeloma January 1, 2016 Phase 1|Phase 2
NCT03034200 Peter Anderson|Case Comprehensive Cancer Center Recurrent Neuroendocrine Tumor|Metastatic Neuroendocrine Tumor February 2017 Phase 2
NCT02324621 Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey|Oncoceutics, Inc. Unspecified Adult Solid Tumor February 2015 Phase 1
NCT02420795 M.D. Anderson Cancer Center|Oncoceutics, Inc. Lymphoma November 3, 2015 Phase 1|Phase 2
NCT03099499 Fox Chase Cancer Center|Oncoceutics, Inc. Endometrial Cancer June 8, 2017 Phase 2
NCT02392572 M.D. Anderson Cancer Center|Oncoceutics, Inc. Leukemia November 2015 Phase 1|Phase 2
NCT02525692 Oncoceutics, Inc. Recurrent Glioblastoma January 2016 Phase 2
NCT03134131 Oncoceutics, Inc. Glioma
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.5874 mL 12.9369 mL 25.8739 mL
5 mM 0.5175 mL 2.5874 mL 5.1748 mL
10 mM 0.2587 mL 1.2937 mL 2.5874 mL
Cell Assay
[1]

TIC10 is prepared in DMSO and stored, and then diluted with appropriate medium before use[1].

Floating and adherent cells are analyzed on a Coulter-Beckman Elite Epics cytometer. For surface TRAIL experiments, adherent cells are harvested by brief trypsinization, fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 20 min, incubated with an anti-TRAIL antibody at 1:250 overnight, washed and incubated with anti-rabbit Alexa Fluor 488 for 30 min, and analyzed. Cells are gated on forward and side scatter to eliminate debris and dead cells from the analysis. Surface TRAIL data are expressed as median fluorescence intensity relative to that of control samples unless indicated otherwise. Surface DR5 is analyzed similarly with an antibody from Imgenex. For sub-G1content and cell cycle profile analysis, all cells are pelleted and ethanol-fixed, followed by staining with propidium iodide in the presence of RNase. Cell viability assays are carried out in 96-well black-walled clear-bottom plates with CellTiter-Glo[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

TIC10 is suspended in 20% Cremophor EL, 10% DMSO, and 70% PBS (Mice)[1].

Mice[1]
For subcutaneous xenografts, 4- to 6-week-old female athymic nu/nu mice are inoculated with 1×106 cells (2.5×106 for T98G) of the indicated cell lines in each rear flank as a 200-μL suspension of 1:1 Matrigel (BD)/PBS. All subcutaneous tumors are allowed to establish for 1 to 4 weeks after injection until reaching a volume of ~125 mm3 before treatment initiation. All intraperitoneal and intravenous injections are given at a total volume of 200 μL. Oral formulations of TIC10 are administered by oral gavage and given as a 200 μL suspension containing 20% Cremophor EL, 10% DMSO, and 70% PBS. Tumors are monitored with digital calipers at indicated time points. All subcutaneous tumors are allowed to establish for 1-4 weeks post-injection until reaching a volume of ~125 mm3 before treatment initiation. Relief of tumor burden is monitored for 3 weeks after disappearance of the tumor and confirmed by visual inspection after euthanasia. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

386.49

Formula

C₂₄H₂₆N₄O

CAS No.

1616632-77-9

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.68%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
TIC10
Cat. No.:
HY-15615A
Quantity: